Prazepam in the treatment of spasticity. A quantitative double-blind evaluation.
D000328:Adult; D001381:Azepines / Q000009:adverse effects; D001552:Benzazepines / Q000008:administration & dosage*; D002713:Chlorine / Q000008:administration & dosage / Q000009:adverse effects; D003521:Cyclopropanes / Q000008:administration & dosage / Q000009:adverse effects; D004558:Electric Stimulation; D004569:Electroencephalography; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009132:Muscles / Q000008:administration & dosage; D013035:Spasm / Q000188:drug therapy*; D013686:Telemetry
D001381:Azepines; D001552:Benzazepines; D003521:Cyclopropanes; D006993:Hypnotics and Sedatives; D002713:Chlorine